secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001140361-25-029998
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q1 loss widens to $0.33/share; completes $1.5B buyback, initiates new $500M program
--------------------------------------------------------------------------------

- GAAP loss from continuing ops $273.9M ($0.33/share) vs income $31.6M ($0.01) YoY; revenue $2.2M down from $8.0M.
- Non-GAAP loss from continuing ops $170.1M vs $107.1M YoY; R&D spend up $32.4M to $152.9M.
- Completed $1.5B share repurchase program; board approved new $500M buyback in June 2025.
- Cash, equivalents, restricted cash and marketable securities $4.5B; shares outstanding reduced >15% from Mar 2024.
- Brepocitinib VALOR DM Phase 3 topline data H2 2025 (LPLV July); IMVT-1402 registrational trials started in GD, SjD June.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/0001140361-25-029998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/ef20053385_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer